• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Dr Reddy's Laboratories News

    74,55 $ +0,72% +0,53 $
    In : 69,719 € | 26.04.24 22:10:00 NYSE aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 659157
    ISIN: US2561352038
    US-Symbol: RDY
    Typ: Aktie

    Dr Reddy's Laboratories News

    22.03.24 - wallstreet:online Zentralredaktion
    Incredible India: Gehört Indien die Zukunft? Aktien, ETFs und Fonds aus dem Land der Gegensätze
    Der indische Markt entwickelt sich stärker als europäische und US-​Leitindizes. Erfahren Sie, welche Faktoren die Entwicklung begünstigen und welche Aktien, ETFs und Fonds zur ...
    13.04.22 - wallstreet:online Zentralredaktion
    Rendite-Liste: Bernstein: Diese Indien-Aktien könnten um zehn Prozent und mehr steigen
    Foto: Free-​Photos - pixabay.com Indische Aktien mit mehr als zehn Prozent Aufwärtspotenzial haben Bernstein-​Analysten gefunden. Eine hätte gar das Potential, um an die 40 ...
    07.09.21 - PR Newswire
    Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
    Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-​Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other ...
    03.06.21 - PR Newswire
    Global Response Aid Reports Midyear Sales Results for COVID Drug
    Global Response Aid Reports Midyear Sales Results for COVID Drug Reports sales of 11 million anti-​viral Avigan® tablets in first seven months PR Newswire
    03.03.21 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire
    02.02.21 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire
    06.02.20 - PR Newswire
    Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170
    Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 - Aurigene to fund and conduct a Phase 2b/3 randomized study of ...
    20.07.19 - PR Newswire
    Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults
    Upsher-​Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults Strategic Acquisition of Tosymra™ (sumatriptan) Nasal Spray and Zembrace® ...
    13.06.19 - PR Newswire
    Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection)
    Upsher-​Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection) Strategic Acquisition ...
    01.05.19 - PR Newswire
    URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders or Former Shareholders To Contact the Firm Immediately
    URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders or Former Shareholders To Contact the Firm Immediately PR Newswire
    19.07.18 - PR Newswire
    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dr. Reddy's Laboratories Limited (RDY)
    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dr. Reddy's Laboratories Limited (RDY) PR Newswire
    15.06.18 - PR Newswire
    Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market
    Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market PR Newswire
    21.03.18 - The Motley Fool
    3 Dinge, die die Investoren von Celgene nach dem Ozanimod-Debakel wissen möchten
    Die Geschichte von Celgene (WKN:881244) könnte aus einem traurigen Country-​Song kommen. Das große Biotech-​Unternehmen hat in den vergangenen sechs Monaten mehr ...
    18.10.17 - PR Newswire
    EQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited
    EQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited PR Newswire
    13.10.17 - PR Newswire
    EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - RDY
    EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - RDY PR Newswire
    11.10.17 - PR Newswire
    DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm
    DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm ...
    22.09.17 - PR Newswire
    DR. REDDY'S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)
    DR. REDDY'S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. ...
    15.09.17 - PR Newswire
    DR. REDDY'S SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Ag
    DR. REDDY'S SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 ...
    06.09.17 - PR Newswire
    IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
    IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with ...
    05.09.17 - PR Newswire
    IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
    IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »